Cerevel Therapeutics Holdings, Inc. (CERE) Q4 2020 Earnings Conference Call March 24, 2021 8:00 AM ET
Company Participants
Matt Calistri - Vice President, Investor Relations
Tony Coles - Chief Executive Officer
Ray Sanchez - Chief Medical Officer
John Renger - Chief Scientific Officer
Kathy Yi - Chief Financial Officer
Conference Call Participants
Paul Matteis - Stifel
Michael Yee - Jefferies
Greg Suvannavejh - Goldman Sachs
Operator
Good morning. Welcome to the Cerevel Therapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call. At this time, all participants are in listen-only mode. [Operator Instructions] Please note that this call maybe recorded. I will now hand the call over to Matt Calistri, Vice President of Investor Relations.
Matt Calistri
Thank you. Good morning, everyone. We appreciate you joining us for our fourth quarter and full year 2020 earnings call. On today’s call, you will be hearing from Dr. Tony Coles, our Chief Executive Officer; Dr. Ray Sanchez, our Chief Medical Officer; Dr. John Renger, our Chief Scientific Officer; and Kathy Yi, our Chief Financial Officer.
During our call today, please refer to our press release from this morning detailing our 2020 performance as well as our updated corporate presentation, both of which are available on our website. I would like to remind you that we will be making forward-looking statements that reflect our current views related to our financial performance, future events and industry and market conditions, as well as forward-looking statements, including the potential attributes and benefits of our product candidates, and the format and timing of Cerevel’s product development activities and clinical trials. We strongly encourage you to review the information that we filed with the SEC regarding specific risks and uncertainties.
I will now hand it over to Dr. Tony Coles, Chairperson and CEO of Cerevel to provide an overview
- Read more current CERE analysis and news
- View all earnings call transcripts